Advancements in Stem Cell Transplants and Artificial Intelligence
Originally Published 2 years ago — by Multiple Sclerosis News Today
A study comparing stem cell transplant with the drug Lemtrada in treating multiple sclerosis (MS) found that stem cell transplant outperformed Lemtrada in terms of MRI activity, relapses, and disability worsening. However, researchers noted that Lemtrada may be effective in halting disability progression in the early stages of highly active relapsing-remitting MS. In another study, an artificial intelligence (AI) tool called iQ-MS showed promise in accurately quantifying MS lesion volume and brain atrophy, outperforming human radiologists in identifying new or enlarging lesions. While AI tools have limitations, they have the potential to enhance MS research and precision management of individual patients.
